Regional access Medis is a fully integrated commercialization partner focused on Central and Eastern Europe, offering an established track record with 150+ reimbursement successes and one point of accountability across 19 markets, presenting a strong opportunity to accelerate market access for partners' therapies in the region.

Partnership depth With a diverse portfolio across Therapeutics, Hospital Care, Consumer Health, and Aesthetics, plus a robust network of major partners and out-licensing collaborations, Medis can broaden partner reach and optimize co-commercialization strategies in multiple segments.

KOL and access Strong relationships with local health professionals and key opinion leaders enable faster patient access and adoption, suggesting opportunities to accelerate launch timelines for rare, specialty, or orphan products requiring local advocacy and reimbursement navigation.

Orphan and rare focus Membership in the World Orphan Drug Alliance and regional distribution expertise position Medis as a capable partner for orphan and specialty portfolios seeking extensive regional coverage across 158 countries via a consolidated commercialization platform.

Growth readiness Evidence of financial stability, a clear value proposition of integrated regulatory to sales and marketing, and a scalable model across 19 markets indicate readiness to scale new brand introductions, out-licensing opportunities, or portfolio expansions with global partners.